You are correct there too....MRK, AZN and Roche will prove to be worthy competitors in immuno-oncology after BMY's fast start. Do you agree with many oncologists that BMY needs to find some co-therapy that will increase RRRs of both Opdivo and Yervoy, without subsequent tumor cell mutations mitigating PFS or OS?
I will be interested to see what may emanate from ESMO in early October as well as MSK and NCCN clinical trials.
News 
Market Data 
Discover 
